The process of discovering chemical entities with the potential to become therapeutic agents is known as drug discovery. All activities involved in transforming a molecule from a drug candidate (the end-product of the discovery phase) to a product licensed for marketing by the competent regulatory authorities are referred to as drug development. The identification of new molecular entities that may be useful in the treatment of diseases that qualify as unmet medical needs is a key goal of drug development programs.
Drug screening is the process of identifying and optimizing potential drugs prior to the selection of a candidate drug for clinical trials. A broad range of analytical assays are used in bioactive compound screening to determine the potential of biological extracts or molecules. The assays might be done on the whole animal, in cells, or at the molecular level. Classic pharmacology, also known as phenotypic drug discovery, which is the historical basis of drug discovery, and reverse pharmacology, or target-based drug discovery, are two complementary approaches to drug discovery.
Title : Innate Immune memory based therapeutics in the resolution of inflammation
Liwu Li, Virginia Polytechnic Institute and State University, United States
Title : Drugs as an environmental problem chromatographic and computational studies of drugs partition between soil and water
Anna Weronika Sobanska, Medical University of Lodz, Poland
Title : Resveratrol derivatives a new tool for osteogenic induction in the treatment of peri implantitis
Barbara De Filippis, University “G. d’Annunzio, Italy
Title : Comparative Study on Inhibition of Pancreatic Cancer Cells by Resveratrol Gold Nanoparticle and Resveratrol Nanoemulsion Prepared from Grape Skin
Bing Huei Chen, Fu Jen Catholic University, Taiwan
Title : Adiposome a Hydrophobic Drug Delivery System
Pingsheng Liu, Chinese Academy of Sciences, China
Title : Targeting breast cancer through prodrug activation by cytochrome P450 1A1
Sebastien Fortin, Laval University, Canada